N Engl J Med 2020; 382:1430-1442 DOI: 10.1056/NEJMoa1912735 List of authors. Andrea M. Gross, M.D., Pamela L. Wolters, Ph.D., Eva Dombi, M.D., Andrea Baldwin, P.N.P., Patricia Whitcomb, R.N., Michael J. Fisher, M.D., Brian Weiss, M.D., […]
Read MoreA young patient with NF1 who was treated at NCI gathers with her mother and members of NCI’s Pediatric Oncology Branch. Credit: National Institutes of Health Over 30 years of NCI-led and NCI-supported research culminated […]
Read MoreInduced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer The study focuses on […]
Read MoreFor Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems. Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions. As […]
Read MoreFor Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems for pre-clinical therapeutic testing. Most in vitro drug testing is performed on cells growing in two dimensions […]
Read MoreAuthor: Cathy Gara. July 2018–The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Shruti Garg, of the University of Manchester, and Dr. Ina Ly, […]
Read MoreThe FY18 Neurofibromatosis Research Program (NFRP) is accepting applications for research projects. Applications to the Fiscal Year 2018 (FY18) Neurofibromatosis Research Program (NFRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development […]
Read MoreNew Research Tools Available in the Search for Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas By Cathy Gara | For Release: June 15, 2018 Plexiform neurofibromas affect up to 50 percent of people with neurofibromatosis […]
Read MoreThe Neurofibromatosis Therapeutic Acceleration Program (NTAP) at The Johns Hopkins School of Medicine is proud to announce that Dr. Angela Hirbe (Washington University) and Dr. Ping Chi (Memorial Sloan Kettering Cancer Center) have been selected […]
Read MoreBethesda, MD (December 28, 2016) NCI Press Release: In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the […]
Read More